Search
Lyell Immunopharma Inc
LYELAdd to Watchlist
14.300USD
-1.340-8.57%
Close 11-13 16:00（ET）
350.49MMarket Cap
LossP/E TTM
Lyell Immunopharma Inc (LYEL) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Lyell Immunopharma Inc in the past month.
Buy
2 Strong Buy
5 Buy
0 Hold
1 Sell
0 Strong Sell
Target Price
37.875USD+243.07%
LYEL Analyst Recommendation Trends
In the current month, LYEL has received 5 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. LYEL average Analyst price target in the last month is 37.875.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
1
1
1
1
0
0
5
5
5
4
4
4
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
8
8
7
6
6
6
4
3
LYEL Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, LYEL EPS is projected to reach -2.140 in FY2026Q4, following reported EPS of -1.863 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-2.37
-2.02
-2.07
-2.14
-2.13
Actual
-1.10
-1.92
-1.86
--
--
Surprise
+53.32%
+5.05%
+10.14%
--
--
FAQs
What is Lyell Immunopharma Inc's expected revenue for the next quarter?
Lyell Immunopharma Inc's expected revenue is 1.25K.
What is Lyell Immunopharma Inc's price target?
Analysts forecast that Lyell Immunopharma Inc's price target is USD 38.38, with the highest forecast at USD 49.00 and the lowest forecast at USD 12.00.
How have Lyell Immunopharma IncLYEL's recent earnings per share performed?
The market expectation was USD -1.86, while Lyell Immunopharma IncLYEL's earnings per share (EPS) for the previous quarter was USD -1.92. EPS for the next quarter is expected at USD -2.14.
What is the analyst rating for Lyell Immunopharma Inc?
Based on the ratings of Lyell Immunopharma Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.